Treatment News : FDA Approves HIV Drug Tivicay (Dolutegravir)

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » August 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


August 13, 2013

FDA Approves HIV Drug Tivicay (Dolutegravir)

The U.S. Food and Drug Administration (FDA) has approved ViiV Healthcare’s Tivicay (dolutegravir), the second approved antiretroviral (ARV) in the integrase strand transfer class after Isentress (raltegravir), MedPage Today reports. The FDA declined to approve a third drug, elvitegravir, as an individual agent in the same class. It has already been approved as a component of the “Quad” pill, Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir), and may eventually be approved as an individual agent.

The FDA gave the green light for Tivicay’s use in both treatment-naive as well as treatment-experienced people with HIV, including those who have taken Isentress. The agency also approved the ARV for use in children ages 12 and up who weigh at least 40 kilograms (88 pounds) and have not taken integrase inhibitors before.

Before making its decision, the FDA considered four Phase III clinical trials including 2,557 participants who were randomly given Tivicay or Isentress in combination with other ARVs, or they were given Atripla (efavirenz/emtricitabine/tenofovir).

Tivicay suppressed HIV at rates equivalent to or better than Isentress. Tivicay is considered a promising alternative because of its once-a-day, 50 milligram dosing, compared with twice-a-day, 400 mg dosing for Isentress.

Tivacy’s common side effects included insomnia and headache. Serious side effects included hypersensitivity reactions and abnormal liver function among those coinfected with HIV and hepatitis B or C.

ViiV Healthcare is a joint effort of GlaxoSmithKline and Pfizer, established in 2009 to pursue advancements in HIV care.

To read the MedPage Today article, click here.

To read the FDA release, click here.

Search: ViiV Healthcare, GSK, GlaxoSmithKline, Tivicay, dolutegravir, Isentress, raltegravir, FDA, Stribild, elvitegravir, cobicistat, emtricitabine, tenofovir, HIV, Quad

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Hide comments

Previous Comments:


[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Has a pet helped you deal with your HIV?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.